Amphastar Pharms Stock
StockStockPrice
Frequently asked questions
What is Amphastar Pharms's market capitalization?
What is Amphastar Pharms's Price-to-Earnings (P/E) ratio?
What is the Earnings Per Share (EPS) for Amphastar Pharms?
What are the analyst ratings and target price for Amphastar Pharms's stock?
What is Amphastar Pharms's revenue over the trailing twelve months?
What is the EBITDA for Amphastar Pharms?
What is the free cash flow of Amphastar Pharms?
What is the 5-year beta of Amphastar Pharms's stock?
How many employees does Amphastar Pharms have, and what sector and industry does it belong to?
What is the free float of Amphastar Pharms's shares?
Financials
Market Cap
$2.35B5Y beta
0.81EPS (TTM)
$3.005Free Float
37.50MP/E ratio (TTM)
16.16Revenue (TTM)
$723.55MEBITDA (TTM)
$266.61MFree Cashflow (TTM)
$170.15MPricing
Analyst Ratings
The price target is $63.25 and the stock is covered by 6 analysts.
Buy
4
Hold
2
Sell
0
Information
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.
1,761
Biotechnology & Drugs
Health Care
Identifier
ISIN
Primary Ticker